Document is current

Article History

Received: 30 July 2025

Accepted: 13 October 2025

First Online: 22 November 2025

Declarations

:

: Raymond Matthews has received contracts or grants from National Institute for Health and Care Research UK, and support for attending meetings and/or travel from UCB and Sanofi. April W Armstrong has received contracts or grants from AbbVie, ASLAN, Bristol Myers Squibb, Dermavant Sciences, Dermira, Eli Lilly, Galderma, Incyte, Janssen, Leo Pharma, Meiji Seika Pharma Co., Ltd, Modernizing Medicine, Nimbus Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Sanofi Genzyme, UCB and Ventyx Biosciences. She has worked as a consultant at AbbVie, ASLAN, Almirall, Amgen, Arcutis Biotherapeutics, Beiersdorf, Bristol Myers Squibb, Dermavant, EPI Health, Eli Lilly, Janssen, LEO Pharma, Mindera, Nimbus, Organon & Co, Sanofi, Sun Pharmaceutical Industries, Takeda and Ventyx Biosciences. April W Armstrong has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Amgen, Bristol Myers Squibb, Galderma, Janssen, Mindera, Organon & Co, Sanofi and Takeda. Lastly, she has been part of a Data Safety Monitoring Board or Advisory Board for Incyte, Regeneron, UCB, Boehringer Ingelheim and Parexel. Matthias Augustin has served as a consultant, lecturer, researcher, and/or has received research grants from companies manufacturing drugs for chronic skin diseases, including AbbVie, Acelyrin, Almirall, Alumnis, Amgen, Aslan, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celldex Therapeutics, Celltrion, Centocor, Coldplasmatech, CSL Behring, Curea, Dermavant, Dermira, Eli Lilly, Galderma, Genzyme, GlaxoSmithKline, Hexal, Incyte, Innovaderm, Janssen, Klinge, Leo Pharma, L’Oréal, MC2, Medac, Meiji, Menlo, Merck, MoonLake Immunotherapeutics, MSD, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Skinuvita, Stallergenes Greer, Sun Pharmaceutical Industries, Takeda, Trevi, UCB and Viatris. Christopher Baker has worked as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Janssen, Leo Pharma, Novartis and UCB Pharma. He has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Amgen, Bristol Myers Squibb, Janssen, Leo Pharma, Novartis and UCB Pharma. Adam Reich has worked as a consultant or speaker for AbbVie, Bausch Health, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz, Sanofi and Trevi, and participated as principal investigator or sub-investigator in clinical trials sponsored by AbbVie, AnaptysBio, Argenx, CellTrion, Drug Delivery Solutions Ltd, Galderma, Genentech, InflaRx, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, Sanofi, Trevi, UCB and VielaBio. Adam Reich is an Editorial Board Member for Dermatology and Therapy . Adam Reich was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. José Manuel Carrascosa has worked as a consultant for AbbVie, Novartis, Leo Pharma, Almirall, Johnson & Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. He has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Novartis, Leo Pharma, Almirall, Johnson & Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. José Manuel Carrascosa has provided expert testimonials for AbbVie, Novartis, Leo Pharma, Almirall, Johnson and Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. He has received support for attending meetings and/or travel from Johnson & Johnson, Lilly and Almirall. Lastly, José Manuel Carrascosa has been part of a Data Safety Monitoring Board or Advisory Board for AbbVie, Novartis, Leo Pharma, Almirall, Johnson & Johnson, UCB, Bristol Myers Squibb, Pfizer, Sanofi, Lilly and Galderma. Jose-Manuel Carrascosa is an Editorial Board Member for Dermatology and Therapy . Jose-Manuel Carrascosa was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Brian Kirby has received grants or contracts from AbbVie, Almirall, Novartis, MoonLake Therapeutics, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz, Union and UCB. He has worked as a consultant for AbbVie, Almirall, Novartis, MoonLake Therapeutics, UCB, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz and Union. Brian Kirby has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Almirall, Novartis, MoonLake Therapeutics, UCB, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz and Union. In addition, he has received support for attending meetings and/or travel from AbbVie, Almirall, Novartis, MoonLake Therapeutics, UCB, AstraZeneca, Janssen, Leo Pharma, Novartis, Pfizer, Sandoz and Union. Brian Kirby has been part of a Data Safety Monitoring Board or Advisory Board for Arctic Bioscience and is a member of the BADBIR Steering Committee and the Clinical Advisory Group at RCPI. Richard Langley has grants or contracts from AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. He has worked as a consultant for AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. In addition, Richard Langley has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. He has been part of a Data Safety Monitoring Board or Advisory Board for AbbVie, Janssen, Amgen, Leo Pharma, UCB, Union, Lilly, Novartis and Boehringer Ingelheim. Lastly, Richard Langley is Chair at Dalhousie UIRMF Investments Endowment and Chair at the Canadian Dermatology Association. Sandy McBride has worked as a consultant for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen Cilag, Novartis, Pfizer and UCB. She has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen Cilag, Novartis, Pfizer and UCB. Sandy McBride has received support for attending conferences from AbbVie, Johnson & Johnson, Eli Lilly and UCB. Ricardo Romiti has worked as a consultant for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Johnson & Johnson, Eli Lilly, Leo Pharma, Novartis, Pfizer, Sanofi, Sun Pharma Industries and UCB. He has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Johnson & Johnson, Eli Lilly, Leo Pharma, Novartis, Pfizer, Sanofi, Sun Pharmaceutical Industries and UCB. Ricardo Romiti has received support for attending meetings and/or travel from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson and UCB. In addition, he has been part of a Data Safety Monitoring Board or Advisory Board for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Leo Pharma, Novartis, Sun Pharma Industries and UCB. Lastly, Ricardo Romiti is an International League of Dermatological Societies (ILDS) Regional Director. Francesca Sampogna has been a consultant for AbbVie. Richard B Warren has received grants or contracts from AbbVie, Almirall, Amgen, Celgene, Janssen, Leo Pharma, Lilly, Novartis, Pfizer and UCB. He has worked as a consultant for AbbVie, Almirall, Amgen, Arena, Astellas, Avillion Life Sciences, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DICE Therapeutics, Eli Lilly, Galderma, GSK, Janssen, Leo Pharma, Lilly, Meiji Pharma, Novartis, Pfizer, RAPT Therapeutics, Sanofi, Sun Pharma Industries, UCB and UNION. Richard B Warren has received payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from AbbVie, Almirall, Janssen, Lilly, Bristol Myers Squibb, Galderma and Novartis. Richard B Warren is an Editor-in-Chief for Dermatology and Therapy . Richard B Warren was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki (1964 and its later amendments). This survey-based study, which involved the collection of anonymised data and voluntary participation, was reviewed by Sermo, London UK (healthcare insights agency), who determined that formal ethical approval was not required for this type of market research [ ].